BUAD 490
3/14/13
Team Written Case Analysis (Concise)
Biodel, Inc.
BIODEL INC.
EXECUTIVE SUMMARY
Biodel’s use of biotechnology expertise in the three prime areas of Cell Biology, Molecular Biology, and Immunodiagnostics has led their company into some great opportunities. Biodel created a synthetic serum to replace fetal calf serum and horse serum, and provide a more consistently available product for scientific researchers. Biodel’s Molecular Biology division used DNA technology to gain 60% of the market share of growth factors and stock the largest collection of commercially available synthetic nucleotides, which was 50% of their sales. Biodel’s research and development in Immunodiagnostics led to the invention of DEMA, a
…show more content…
Feldman usually assuming all of the major marketing responsibilities. But when Dr. Feldman decided that he needed to market his company more aggressively he hired Mr. Steve Kaplan who had been a marketing manager at a large pharmaceutical company. However, Mr. Kaplan and Dr. Feldman soon disagreed on who should direct Biodel's marketing strategy. Kaplan proceeded to spend a large amount of money on marketing, including hiring additional salespeople and other staff. These changes resulted in a 65% increase in sales, but marketing costs increased by 500%, which resulted in profits dropping from $95,000 in 1978 to $17,000 in 1979. As a result, Dr. Feldman is reconsidering Mr. Kaplan's direction in the marketing department.
OPPORTUNITIES
First, Biodel had under development a synthetic serum that would be used to satisfy growth requirements in cells. This would be an innovative product that could be a substitute for natural fetal calf serum and horse serum. However, a major problem with the fetal serum is the unstable fluctuation in cost. The cost is determined by the supply of the serum and the supply is determined by the number of calves that are slaughtered. The synthetic serum could offer a steady rate. The market is projected at $50 to $80 million. Biodel would have a competitive advantage over the competition and could attain 20% of the market share if they pursue this project. A big problem with this
37. What happens if you don’t have enough The body’s calcium needs will come out of the
Faboil Ltd has evolved into a relatively successful organisation in the biotechnology field. The success of the company and its paternal approach was adopted by Dr Alfred Brownlow. Dr Brownlow has led from the front in terms of developing the product range for Faboil Ltd. Richard Cranberry (Director of Biotechnology) has driven very hard to maintain the success of the company, although the organisation lag behind in terms of modus operandi technology. At present, the monopoly position of Faboil Ltd has slowly eroded away and faces two competitors. The major causes are that the new products have failed to live up to market expectations and it is at a backward stage only holding a 20% market share. This report will find the
1. In no more than one-page, describe Biometra and the industry that this company is in.
Cellular respiration: C6H12O6 + 6O2 → 6CO2 + 6 H2O + 36 or 38 ATP
1. Describe the function of the following pieces of safety equipment and how each might be used: (10 points)
3. State the name and structure of the functional group for each type of biologically
Please answer these questions then place them in the drop box for this lab. Use Microsoft word if possible.
# of plaques/(volume plated x reciprocal of the dilution factor of the dilution tube used)
Hydrolysis of starch for fungal amylase Aspergillus Oryzae and bacterial amylase Bacillus Licheniformis at different temperatures.
When using Snort IDS, there are several modes that if configured properly, will generate alerts. Alerts are set by the user within the command prompt when initiating a rule set. There are five alerting options available with Snort IDS. According to (Roesch, 1999), Alerts may either be sent to syslog, logged to an
The key issue is to determine when Oxyglobin should be introduced to the market without jeopardizing Hemopure’s potential and how it should be marketed.
The purpose of this experiment was to observe how calf serum affected cell proliferation. It was hypothesized that various concentrations of Fetal Bovine Serum (FBS) would provide nutrients for non-transformed cells, and therefore affect their growth, but have no effect on the transformed cells. It was also hypothesized that the protein concentrations will increase for the non-transformed cells upon addition of the calf serum and FGF, but not affect the transformed cells since they are not dependent on growth factors. After analyzing the results, it can be concluded that increasing FBS concentrations does in fact increase non-transformed cell density. Transformed cells are unaffected by this concentration as is proven by the results since the cell densities are roughly the same at the differing concentrations of FBS (0.5%, 2%, and 10%). Furthermore, since the ERK1/2 factor is increased in the non-transformed cells, the cell density will also increase.
There are several rewards to consider with expansion of Biocon. Currently in India, there is a growing market for contract research organization and the growth of Biocon falls right within this opportunity. The growth is expected to last for more than few years with a rate that looks promising. Clinigene is expected to reap revenues much higher than the current Biocon and Syngene combined (Kalegaonkar A., Nov 4, 2008). It will take clinical studies to a higher level with better options in terms of drug manufacturing. With other countries ready to outsource the service of clinical studies, Clinigene’s future looks bright.
Comparing these potential market size, we can easily observe that Oxyglobin is roughly two times as profitable as Hemopure. Accordingly, Biopure should take these data into account to evaluate whether or not to launch Oxyglobin immediately. On the other hand, this revenue expectation is not so realistic. In fact, it is almost impossible that the company will capture the whole potential markets because of its small production capacity. This latter represents the main obstacle to a potential success of Biopure in both animal and human
There are three types of environments in which cells are located which include isotonic, hypotonic and hypertonic. In an isotonic environment, the amount of water and solute are the same both inside and outside of the cell. As water drifts into the a cell, the same amount flows out creating a balanced environment both inside and outside of the cell. When there is a high level of water on the outside of the cell and a high amount of solute inside the cell, water will be drawn inside of the cell creating a hypotonic solution. The increase in water inside the cell causes the cell to become engorged and erupt. In a